Nuzenio

Amylin Agonist

Amylin Agonist news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 3 latest news signals 2 publisher sources 100/100 entity strength

Latest news

Ascletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - BioPharm InternationalBioPharm International · Mon, 10 Aug 2026 19:50:09 GMT Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR NewswirePR Newswire · Mon, 10 Aug 2026 11:00:00 GMT Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination - PR NewswirePR Newswire · Mon, 03 Aug 2026 10:55:00 GMT

Timeline

Mon, 10 Aug 2026 19:50:09 GMTAscletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - BioPharm International

Mon, 10 Aug 2026 11:00:00 GMTAscletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR Newswire

Mon, 03 Aug 2026 10:55:00 GMTAscletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination - PR Newswire

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Formulation4 live mentions Once4 live mentions Monthly Injection4 live mentions GLP4 live mentions Obesity3 live mentions Studies3 live mentions Its GLP2 live mentions GIP Co2 live mentions Ascletis Announces Initiation2 live mentions Two Phase I2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Amylin Agonist.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.